Life Science and Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
305 909 0840
https://longeveron.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 23
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 74k | N/A | 1963 |
Mr. Mohamed Wa'el Ahmed Hashad | CEO & Director | 781.56k | N/A | 1962 |
Ms. Lisa A. Locklear M.B.A. | Executive VP & CFO | 248.38k | N/A | 1962 |
Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 554.05k | N/A | 1968 |
Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | N/A | N/A | 1971 |
Dr. Nataliya Agafanova M.D. | Chief Medical Officer | N/A | N/A | 1970 |
Ms. Elly Ryu | VP & Corporate Controller | N/A | N/A | 1982 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.